In the expanding frontier of obesity medicine, Eli Lilly has announced that its oral weight-loss drug Foundayo has captured more than 30 percent of new patients entering the US oral GLP-1 market — a striking early milestone that reflects both the hunger for convenient treatment options and the intensifying competition reshaping how the world addresses chronic weight conditions. The achievement positions Lilly as a serious rival to Novo Nordisk, whose injectable dominance has long defined the category. Yet in a market still finding its shape, a strong opening is a beginning, not a verdict.